Neuroendocrine carcinomas are rare tumors. In the head and neck region they are most common in the larynx, where they represent 0.5-1% of epithelial cancers. Diagnosis requires the recognition of the typical neuroendocrine architecture and morphology and the immunohistochemical confirmation of neuroendocrine differentiation. In the 1991 WHO classification laryngeal neuroendocrine carcinomas hav...

The entity known as pituitary carcinoma has been traditionally defined a tumor of adenohypophysial cells that metastasizes systemically or craniospinally independent the histological appearance lesion. Reported cases have clinically and histologically resembled their non-metastatic counterparts were classified adenomas; majority initially diagnosed adenomas, with progression spread, diagnosis w...

1. Incipient neuroendocrine neoplasia: Dysplasia/Tis 2. True neuroendocrine tumors a. Well differentiated NETs (carcinoids, pancreatic neuroendocrine neoplasms) b. High-grade neuorendocrine carcinoma 3. Hybrid tumors a. Mixed tumors i. Mixed adenocarcinoma-neuorendocrine carcinoma ii. Mixed neuorendocrine tumor and non-neuroendocrine carcinoma iii. Duodenal gangliocytic paraganglioma b. Inciden...

BACKGROUND/AIMS Gastrointestinal and pancreatic neuroendocrine tumors (GEPNETs) originate from the cells of the endocrine system. Their molecular genetic mechanism of development and progression is complex and remains largely unknown. The purpose of this study was to review the gastrointestinal and pancreatic neuroendocrine tumors and to evaluate p53, Ki-67 and CD 117 expressions with their cli...

abstract primary neuroendocrine carcinoma of the breast is a very rare malignant tumor. there are not many cases reported in the english literature since it was first documented in 1983. reports on the imaging features, in particular the ultrasonographic features of this rare tumor are scarce. herein, we report a case of aggressive primary infiltrating neuroendocrine carcinoma of the breast, ma...

OBJECTIVE No standard treatment has been established for poorly differentiated neuroendocrine carcinoma; the usual recommended treatment is based on the strategy for small cell lung carcinoma. The aim of this study was to evaluate the response of poorly differentiated neuroendocrine carcinoma to the combination of irinotecan and cisplatin in one institution. METHODS We retrospectively reviewe...

CONTEXT Poorly differentiated neuroendocrine carcinoma of the pancreas is a rare and aggressive tumor. The combination of etoposide and cisplatin is considered as the first-line treatment, but no recommendations exist for further treatment after progression. CASE SERIES We report here case series of three patients who received gemcitabine as salvage chemotherapy in patients with poorly differ...

Amphicrine carcinoma is rarely reported in literature. It characterised by dual positivity of neuroendocrine markers and mucin stain the same cells depicting divergent differentiation. Recently published WorldHealth Organisation (WHO) classification neoplasm 2022 differentiates it from adenocarcinoma mixed neuroendocrine-nonneuroendocrine neoplasms (MiNEN) shows varied histomorphology on rare o...

Large cell neuroendocrine carcinoma (LCNEC) is a poorly differentiated that typically arises in the lung. Because of its rarity and poor prognosis, standardized treatment has not been established yet. A 53-year-old male was initially diagnosed as maxillary sinus squamous (SCC) arising from inverted papilloma (clinical stage T4bN2bM0, IVb), underwent concurrent chemoradiotherapy. After achieving...